Graphite Bio Next-Gen Gene Editing to Cure Genetic Diseases
Kim Drapkin has over 25 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. Garrett brings more than 25 years of industry experience leading high-performing, cross-functional teams at global biopharmaceutical companies to advance the development and life-cycle management of pipeline and approved therapies. Karsen served as the chief executive officer of the Celgene Cellular Therapeutics division of Celgene Corporation and as executive vice president and chief operations officer of Celgene Corporation. Kim Drapkin is the Chief Executive Officer of Graphite Bio. Kristen Hege is a renowned physician-scientist and a pioneer in advancing cell therapies through clinical development to regulatory approval. Joe Jimenez is the former chief executive officer of Novartis, one of the world’s leading pharmaceutical companies. Matthew Porteus is an academic founder of Graphite Bio and a pioneer in the field of gene editing. Carlo Rizzuto is a seasoned biopharmaceutical business executive and investor with over 2 decades of diverse leadership experience.
Keywords
Industries
Where is Graphite Bio located?
The company Graphite Bio is located in South San Francisco, California, United States. It's worth noting that the company may has more corporate locations
How many employees does Graphite Bio approximately have?
As of the latest available information Graphite Bio has around 101-250 employees worldwide.
When was Graphite Bio founded?
Graphite Bio was founded in 2020
In which industries does Graphite Bio mainly work?
The company Graphite Bio has it's main focus in the industries of Biotechnology, Science and Engineering
What is the current company status of Graphite Bio?
Based on the founding year and the amount of employees the company Graphite Bio seems to be a Medium-Sized Company at the current state. Note that over time that status can change
Generation Bio
United States
101-250 Employees
2016
Esya
United Kingdom
1-10 Employees
2018
Nimbus Therapeutics
11-50 Employees
2009
GeneTether
United States
1-10 Employees
2018
Maze Therapeutics
United States
11-50 Employees
2018
Prime Medicine
United States
51-100 Employees
2019
R3 Vascular Inc.
Abeona Therapeutics
United States
51-100 Employees
1989
Topics which have been searched by others and may be interesting for you: